4th-Generation Targeted Therapy for Lung Cancer (NSCLC)
ONCOBIX's research is committed to bringing better progress.
Developing 4th-Generation Targeted Therapy for Lung Cancer
ONCOBIX is developing the 4th-generation of targeted lung cancer drugs for which there is currently no standardized treatment.
Targeted EGFR Gene Mutation
Overcoming Resistance to 3rd-generation Drugs
ONCOBIX is developing innovative NSCLC therapies that would overcome the resistance to the 3rd-generation lung cancer treatments and target EFGR, the known cause of lung cancer.Main Pipelines OBX02 SERIES